With more than 1,000 clinical trials for cell and gene therapies in process and predictions that such products will generate $12 billion in revenue annually by 2025, leaders for pharmaceutical companies and health plans must consider how to make gene therapies financially accessible to those who need them. According to Cotiviti Executive Vice President of Operations Jordan Bazinsky, this is an opportunity to explore a new paradigm for reimbursement for complex therapies—one that is informed by collaborative partnership, with careful consideration of the best way to pay for value.

Traditional management tools have proven to be ineffective at managing costs for oncology drugs, leading to a hands-off management approach in the United States. But a recent survey from Two Labs – including 25 Pharmacy Directors and Medical Directors at US insurance companies representing 112.5 million covered lives – shows that the situation might be changing. The survey aimed to gather insight about what the industry looks like with increased levels of care management by covering traditional management tools, oncology-specific tools, systemic management tools and shifting risk, value frameworks, and pathways of care.

As the grip of the pandemic eases, managed market executives on the pharma and agency side will have to modify their tactics with payers due to changed habits; at the same time, payers’ expectations of value remain strong.

It’s hard to address something that you cannot define. Rare disease management is a high priority for payers. In a recent rare disease trend report, 90% of surveyed payer respondents ranked rare disease management as a high or moderate priority. This is due primarily to the significant budget impact of therapies that may be in the hundreds of thousands of dollars

Dentsu International announced on April 20 the launch of dentsu health, a global solution. Drawing upon the expertise of dentsu’s global network of 2,000 health marketing experts across 85 markets in EMEA, APAC and the Americas, dentsu health is poised to become one of the top global healthcare agencies.

FCB Health Network president & CEO Dana Maiman announced Jill Lesiak joined Mosaic Group – the Network’s full-service payer and market access healthcare agency – as executive creative director.

Zolgensma’s successful market uptake by payers may hold lessons for other manufacturers of costly gene therapies.

What are payers focusing on in the time of stay-at-home, work-from-home, yet still trying to serve patients? What do manufacturers need to understand? Med Ad News spoke with Greg Novello, executive VP, strategy at McCann Health Managed Markets; Adrian Garcia, senior VP, managed markets, at GSW; and Katherine Seay, executive VP, managing director, managed markets communications, Syneos Health.

Leading pharmaceutical business and marketing publication Med Ad News announces the nominees for the 31st Annual Manny Awards, honoring the best in healthcare advertising and communications. Now, more than ever, the role of effectively communicating the research, development, administration and efficacy of drug therapies to HCPs, Payers and Patients alike, is paramount to successfully navigating the world through this pandemic and beyond.

Global healthcare communications agency Fishawack Health acquired Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the United States.